Anteris Reports Q2 2026 Results and Corporate Update
Key points
- Secured U.S. Medicare reimbursement for PARADIGM Trial.
- Initiated U.S. recruitment in the PARADIGM Trial.
- Expanded PARADIGM Trial recruitment across multiple countries.
- Appointed new board members to strengthen governance.
Full summary
Anteris Technologies Global Corp. reported its financial results for the second quarter of 2026, announcing significant progress in its global pivotal PARADIGM Trial. The company secured U.S. Medicare reimbursement eligibility for the trial, initiated patient enrollment in the U.S., and expanded recruitment to Denmark, the Netherlands, Canada, and France. Additionally, Anteris appointed two new members to its Board of Directors, enhancing governance and leadership as the company progresses toward commercialization. The company also presented clinical and scientific progress at New York Valves 2026, showcasing the DurAVR® THV's clinical experience.
Guidance
Net operating cash outflows for Q2 2026 were $20.8 million.
Outlook
Anteris expects continued advancements in the PARADIGM Trial, with ongoing U.S. site activation and patient recruitment activities.
Summary generated by a large language model. Please interpret with care.